Spencer 1992.

Methods	A cohort study of methylphenidate use for 14.2 (SD 10.7) months
Participants	Number of participants screened: not stated Number of participants included: 29 Number followed up: 29 Number of withdrawals: not stated Diagnosis of ADHD: DSM‐III‐R (subtype: not stated) Age: mean 7.8 SD 2.4 IQ: not stated Sex: not stated Methylphenidate‐naïve: not stated Ethnicity: not stated Country: USA Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria: 1. DSM‐III‐R diagnosis of ADHD
Interventions	Methylphenidate type: immediate release Mean methylphenidate dosage: 31.4 (SD 17.6) mg (1 mg/kg SD 0.5) Administration schedule: not stated Duration of intervention: 14.2 (SD 10.7) months Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Assessment of growth deficits: simple growth deficit, percent deficit, change in cumulative frequency percentiles, percent change, standardised height deficit, deficits in growth velocity Malnutrition index
Notes	Sample calculation: not stated Ethics approval: not stated Funding/vested interest: not stated Authors' affiliations: not stated Key conclusions of the study authors: although there were statistically significant weight deficits in children treated with both desipramine and methylphenidate compared with normal controls, only those treated with methylphenidate sustained height deficits that attained statistical significance Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information requested through personal email correspondence with the authors in September and October 2013. No reply